Drug Trial Radar · NCT05929664
Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
70
Planned (sponsor's estimate)
Start
Jul 5, 2023
Primary completion
Jul 5, 2031
Study completion Jul 5, 2031
Sponsor
- Lead sponsor
- Thomas Jefferson UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jul 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A non-randomized two-cohort study of neoadjuvant Cemiplimab or neoadjuvant Cemiplimab plus Fianlimab (CF) in patients with basal cell carcinoma of the head and neck. Enrollment in the dual-therapy cohort will begin after completion of enrollment in the monotherapy cohort. Patients will undergo at least 2 and up to 6 infusions of immunotherapy prior to surgical resection. If patients have progression on neoadjuvant treatment, they may switch to standard of care surgical resection or hedgehog inhibitors prior to surgery. The primary endpoints are objective response rate and disease control rate. Safety and surgical benefit rate (de-escalation of surgery) with preservation of key anatomic structures are secondary endpoints. Correlative endpoints include analysis of pre and post treatment primary tumor and blood samples compared for histology, tumor genetics and immune cell composition.
Conditions
- Locally Advanced Basal Cell Carcinoma
- Basal Cell Carcinoma
Interventions
CemiplimabBiological
Given IV
Computed TomographyProcedure
Undergo CT scan
Biospecimen CollectionProcedure
Undergo collection of blood samples
Quality-of-Life AssessmentOther
Ancillary studies
Magnetic Resonance ImagingProcedure
Undergo MRI
BiopsyProcedure
Undergo biopsy
FianlimabBiological
Fianlimab (REGN3767) administered intravenously in combination with Cemiplimab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Up to 6 months post surgery (up to Day 309 +/- 3 days)
- Disease control rate (DCR)Time frame: Up to 6 months post surgery (up to Day 309 +/- 3 days)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Miami Health System
Miami, Florida
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Vanderbilt University
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.